Holen Sie sich die Stockscreener-App
3.34
0.90%
0.00
Handel nachbörslich:
3.37
0.03
+0.90%
Schlusskurs vom Vortag:
$3.34
Offen:
$3.26
24-Stunden-Volumen:
29,533
Relative Volume:
0.38
Marktkapitalisierung:
$53.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1698
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
+1.20%
1M Leistung:
-2.88%
6M Leistung:
+32.16%
1J Leistung:
-1.17%
1-Tages-Spanne:
$3.25
$3.39
1-Wochen-Bereich:
$3.06
$3.483
52-Wochen-Spanne:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.34 | 53.10M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
An Overlooked Crisis in Hospitals Could Be Pharma's Next Great Opportunity - MarketScreener
What indicators show strength in PolyPid Ltd.Global Markets & Daily Chart Pattern Signal Reports - newser.com
How to use a screener to detect PolyPid Ltd. breakoutsMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for PolyPid (NASDAQ:PYPD) - MarketBeat
Analyzing recovery setups for PolyPid Ltd. investors2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Is this a good reentry point in PolyPid Ltd.2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Best data tools to analyze PolyPid Ltd. stockMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Increase in Short Interest - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - MarketBeat
Price action breakdown for PolyPid Ltd.July 2025 Spike Watch & Long-Term Investment Growth Plans - newser.com
Will PolyPid Ltd. see short term momentumBuy Signal & Stock Portfolio Risk Management - newser.com
Tools to monitor PolyPid Ltd. recovery probabilityBreakout Watch & Safe Capital Investment Plans - newser.com
Is PolyPid Ltd a good long term investmentMid Cap Growth Trends & Achieve Consistent Profits - earlytimes.in
PolyPid to present phase 3 SHIELD II trial results at ACS congress - Investing.com Nigeria
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 By Investing.com - Investing.com Australia
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 - Investing.com India
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - The Manila Times
PolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical Congress - Quiver Quantitative
PolyPid to Present Its Positive Phase 3 SHIELD II Topline - GlobeNewswire
PolyPid (NASDAQ:PYPD) & Cronos Group (NASDAQ:CRON) Head to Head Survey - Defense World
What analysts say about PolyPid Ltd stockVolume Analysis Techniques & Invest Smarter With Data-Driven Models - earlytimes.in
What drives PolyPid Ltd stock priceFibonacci Retracement Levels & Free Rapid Growing Investment Returns - earlytimes.in
PolyPid Ltd. (NASDAQ:PYPD) Receives $12.40 Consensus PT from Analysts - Defense World
PolyPid (NASDAQ:PYPD) Rating Increased to Hold at Wall Street Zen - MarketBeat
What to expect from PolyPid Ltd. in the next 30 days2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9%Time to Buy? - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9% – Time to Buy? - Defense World
Will a bounce in PolyPid Ltd. offer an exitBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
Multi factor analysis applied to PolyPid Ltd.Exit Point & Verified High Yield Trade Plans - newser.com
Real time breakdown of PolyPid Ltd. stock performanceMarket Rally & AI Driven Price Predictions - newser.com
Does PolyPid Ltd. show high probability of reboundExit Point & Safe Entry Trade Signal Reports - newser.com
Strategies to average down on PolyPid Ltd.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
PolyPid completes Israeli Ministry of Health GMP inspection - MSN
PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements - msn.com
Is PolyPid Ltd. forming a reversal patternRisk Management & Weekly High Return Stock Opportunities - newser.com
Decliners Report: Can PolyPid Ltd. ride the EV waveWeekly Market Report & Entry Point Strategy Guides - خودرو بانک
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):